Metronomic chemotherapymay be active in heavily pre-treated patients withmetastatic adreno-cortical carcinoma

Journal of Endocrinological Investigation

Volumn 36, Issue 3, 2013, Pages 148-152

  Ferrero, A ^a   Sperone, P ^a   Ardito, A ^b   Rossi, G ^c   Del Buono, S ^c   Priola, A M ^b   Bracarda, S ^c   Taberna, E ^a   Terzolo, M ^b   Berruti, A ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Arezzo Hospital   (Italy)

Author keywords

Adreno cortical carcinoma; Cyclophosphamide; Etoposide; Metronomic chemotherapy; Mitotane

Indexed keywords

ANDROSTENEDIONE; CAPECITABINE; CYCLOPHOSPHAMIDE; ESTROGEN; ETOPOSIDE; GEMCITABINE; KI 67 ANTIGEN; MITOTANE; PACLITAXEL; SORAFENIB; STREPTOZOCIN; TESTOSTERONE; ANTINEOPLASTIC AGENT;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; ANDROSTENEDIONE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCRINE SURGERY; ESTROGEN BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METRONOMIC CHEMOTHERAPY; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ADRENAL CORTEX TUMOR; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; PATHOLOGY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, METRONOMIC; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84876217581     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8334     Document Type: Article

References (14)

1. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119: 161-70.
2. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 2001, 25: 891-7.
3. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006, 91: 2027-37.
4. Berruti A, Ferrero A, Sperone P, et al. Emerging drugs for adrenocortical carcinoma. Expert Opin Emerg Drugs 2008, 13: 497-509.
5. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4: 423-36.
6. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010, 17: 445-53.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-16.
8. Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012, 166: 451-8.
9. Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma. A large prospective phase II trial. Endocr Relat Cancer 2005, 12: 657-66.
10. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007, 177: 2136-40.
11. Borne E, Desmedt E, Duhamel A, et al. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 2010, 28: 684-9.
12. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008, 99: 459-66.
13. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results. Cancer Res 2010, 180: 165-83.
14. Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011, 96: 1844-51.